Profund Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.6M Buy
23,398
+261
+1% +$116K 0.32% 42
2026
Q1
$10.3M Sell
23,137
-5,681
-20% -$2.65M 0.38% 37
2025
Q4
$13.1M Buy
28,818
+2,423
+9% +$1.04M 0.4% 36
2025
Q3
$10.3M Sell
26,395
-958
-4% -$400K 0.34% 49
2025
Q2
$12.2M Buy
27,353
+2,682
+11% +$1.24M 0.44% 37
2025
Q1
$12M Sell
24,671
-3,903
-14% -$1.82M 0.52% 34
2024
Q4
$11.5M Buy
28,574
+654
+2% +$303K 0.42% 38
2024
Q3
$13M Sell
27,920
-1,626
-6% -$781K 0.49% 32
2024
Q2
$13.8M Buy
29,546
+3,194
+12% +$1.39M 0.51% 31
2024
Q1
$11M Sell
26,352
-1,730
-6% -$731K 0.43% 36
2023
Q4
$11.4M Buy
28,082
+3,495
+14% +$1.29M 0.49% 33
2023
Q3
$8.55M Buy
24,587
+4,653
+23% +$1.63M 0.47% 34
2023
Q2
$7.01M Buy
19,934
+967
+5% +$326K 0.38% 39
2023
Q1
$5.98M Sell
18,967
-22,299
-54% -$6.69M 0.37% 42
2022
Q4
$11.9M Sell
41,266
-18
-0% -$5.49K 0.77% 21
2022
Q3
$12M Sell
41,284
-2,018
-5% -$581K 0.86% 19
2022
Q2
$12.2M Sell
43,302
-5,796
-12% -$1.55M 0.77% 23
2022
Q1
$12.8M Sell
49,098
-9,510
-16% -$2.26M 0.54% 30
2021
Q4
$12.9M Sell
58,608
-8,612
-13% -$1.67M 0.42% 41
2021
Q3
$12.2M Buy
67,220
+37
+0.1% +$7.22K 0.41% 39
2021
Q2
$13.5M Sell
67,183
-2,206
-3% -$461K 0.46% 39
2021
Q1
$14.9M Sell
69,389
-1,990
-3% -$437K 0.57% 26
2020
Q4
$16.9M Buy
71,379
+5,230
+8% +$1.2M 0.74% 21
2020
Q3
$18M Sell
66,149
-8,501
-11% -$2.35M 0.93% 17
2020
Q2
$21.7M Buy
74,650
+9,783
+15% +$2.65M 1.21% 15
2020
Q1
$15.4M Sell
64,867
-21,092
-25% -$4.84M 1.16% 14
2019
Q4
$18.8M Buy
85,959
+8,698
+11% +$1.76M 0.82% 19
2019
Q3
$13.1M Sell
77,261
-4,059
-5% -$718K 0.66% 22
2019
Q2
$14.9M Sell
81,320
-6,390
-7% -$1.12M 0.71% 18
2019
Q1
$16.1M Buy
87,710
+1,342
+2% +$248K 0.78% 17
2018
Q4
$14.3M Sell
86,368
-20,840
-19% -$3.61M 0.89% 18
2018
Q3
$20.7M Buy
107,208
+9,424
+10% +$1.68M 0.78% 18
2018
Q2
$16.6M Sell
97,784
-4,648
-5% -$720K 0.66% 22
2018
Q1
$16.7M Sell
102,432
-7,484
-7% -$1.22M 0.66% 25
2017
Q4
$16.5M Sell
109,916
-11,097
-9% -$1.64M 0.64% 24
2017
Q3
$18.4M Buy
121,013
+9,680
+9% +$1.46M 0.77% 20
2017
Q2
$14.3M Sell
111,333
-6,177
-5% -$744K 0.65% 21
2017
Q1
$12.8M Sell
117,510
-7,989
-6% -$703K 0.57% 26
2016
Q4
$9.25M Sell
125,499
-16,592
-12% -$1.35M 0.43% 35
2016
Q3
$12.4M Sell
142,091
-5,790
-4% -$547K 0.59% 26
2016
Q2
$12.7M Sell
147,881
-6,508
-4% -$562K 0.62% 21
2016
Q1
$12.3M Sell
154,389
-34,724
-18% -$3.14M 0.64% 23
2015
Q4
$23.8M Buy
189,113
+1,006
+0.5% +$121K 1.13% 14
2015
Q3
$19.6M Sell
188,107
-10,171
-5% -$1.31M 1.12% 14
2015
Q2
$24.5M Sell
198,278
-891
-0.4% -$112K 1.01% 15
2015
Q1
$23.5M Buy
199,169
+12,336
+7% +$1.48M 0.91% 15
2014
Q4
$22.2M Buy
186,833
+18,707
+11% +$2.11M 0.91% 14
2014
Q3
$18.9M Buy
168,126
+13,893
+9% +$1.32M 0.88% 16
2014
Q2
$14.6M Sell
154,233
-38,354
-20% -$2.69M 0.64% 21
2014
Q1
$13.6M Buy
192,587
+34,251
+22% +$2.71M 0.62% 21
2013
Q4
$11.8M Buy
158,336
+31,950
+25% +$2.22M 0.53% 18
2013
Q3
$9.58M Sell
126,386
-8,093
-6% -$644K 0.51% 20
2013
Q2
$10.7M Buy
+134,479
New +$9.9M 0.76% 16

Other funds holding VRTX

Profund Advisors's VRTX Position: Q2 2026 in Review

Profund Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, buying an estimated $116K and bringing the position to 23,398 shares worth $11.6M. The position accounts for 0.32% of the portfolio, ranked #42.

Profund Advisors first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $24.5M in Q2 2015. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Profund Advisors held 23,398 shares of Vertex Pharmaceuticals worth $11.6M as of Q2 2026.
  • Profund Advisors bought 261 Vertex Pharmaceuticals shares in Q2 2026, an estimated $116K.
  • Vertex Pharmaceuticals made up 0.32% of Profund Advisors's portfolio in Q2 2026, its #42 holding.
  • Profund Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Profund Advisors's Vertex Pharmaceuticals position peaked at $24.5M in Q2 2015.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.